Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study - Concepedia

Concepedia

Publication | Closed Access

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study

491

Citations

14

References

2007

Year

Sten Nilsson, Lars Franzén, Christopher Parker, Christopher Tyrrell, René Blom, Jan Tennvall, Bo Lennernäs, Ulf Petersson, Dag Clement Johannessen, M. Sokal,

The Lancet Oncology

Bone-targeted Radium-223UrologyGenitourinary CancerMedicineCancer TreatmentProstatic DiseaseOncologyRadiation OncologyHormone-refractory Prostate Cancer

References

	Year	Citations

Page 1

Page 1